Core Points - The company has established a fundraising management system to regulate the use and management of raised funds, enhance their efficiency, and protect investors' rights [2][3] - The system is based on relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2] - The board of directors is responsible for establishing internal control systems for the storage, use, and management of raised funds [2][3] Fundraising Storage - Raised funds must be stored in a special account approved by the board of directors, and separate accounts should be set up for multiple financings [7][8] - A tripartite supervision agreement must be signed with the sponsor and the commercial bank within one month of the funds being received [8][9] - The company must report to the Shanghai Stock Exchange within two trading days after signing the agreement [4][5] Fundraising Usage - The company must follow specific requirements for using raised funds, including clear application procedures and adherence to the planned usage stated in the issuance documents [10][11] - Any significant changes affecting the normal use of funds must be reported to the Shanghai Stock Exchange [10] - The company is prohibited from using raised funds for financial investments or providing funds to related parties [11][12] Changes in Fundraising Purpose - Any changes in the purpose of raised funds must be approved by the board of directors and disclosed to the Shanghai Stock Exchange [22][23] - The company must conduct feasibility analyses for new projects and ensure that they align with the main business [23][24] - If a project is canceled or terminated, the company must report the reasons and the amount of funds used [15][22] Management and Supervision of Fundraising - The company must accurately disclose the actual use of raised funds and maintain detailed records [27][28] - Internal audits should be conducted at least biannually to ensure compliance with the fundraising management system [16][17] - The sponsor is required to conduct on-site investigations of the fundraising management at least biannually [30][31]

国金证券股份有限公司 公司新增募集资金专户的开设情况具体如下： | | | | | 存 入 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 公司名称 | 募集资金专户存储银行 | | | 账号 | | | 用途 | | | | | | 金 | | | | | | | | | 额 | | | | | | 汇丰银行（中国）有限公司 | | | | | | 爱柯迪 | | 爱柯迪（马来西 | | | 020-093811-057 | | 0 | 智能制 | | | 亚）有限公司（IKD | | | | | | | | | (MALAYSIA) | | | | | | | | | | | | | | 产业园 | | | | SDN.BHD.） | INDUSTRIAL | AND | | | | | | 项目 COMMERCIAL BANK OF 关于爱柯迪股份有限公司 新增募集资金专项账户并签署监管协议的核查意见 国金证券股份有限公司（以下简称"国金证券"或"保荐机构"）作为爱柯 迪股份有限公司（以下简称"爱柯迪"或"公司"）公开发行可转换公司 ...

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the status of the funds raised by Seirus Medical Technology Group Co., Ltd. It highlights the termination of certain fundraising projects and the reallocation of remaining funds to enhance liquidity and operational efficiency in response to changing market conditions. Fundraising Overview - In 2018, the company raised approximately RMB 625.96 million through a non-public offering of A-shares, with a net amount of RMB 607.61 million after expenses [1][2] - As of June 30, 2025, the remaining balance of the non-public fundraising was RMB 8.99 million, including interest [2] Fund Usage and Management - By June 30, 2025, the company had utilized RMB 202.78 million of the funds raised from the 2020 convertible bond issuance, leaving a balance of RMB 333.89 million [4] - The company has established dedicated bank accounts for the management of the raised funds, ensuring compliance with regulatory requirements [7][18] Project Termination and Fund Reallocation - The company decided to terminate the "Expansion of Medical Testing Integrated Marketing and Service Business Scale Project" due to significant changes in the market environment and profitability concerns, reallocating the remaining RMB 172.54 million to enhance liquidity [28][29] - The decision was made after thorough evaluations and was approved in board meetings held in June 2025 [28] Financial Management Practices - The company has implemented a structured approach to manage the raised funds, including regular audits and checks by the finance department to ensure proper usage [7][24] - The company has also utilized idle funds temporarily to supplement working capital, with repayments made as scheduled [24][31] Regulatory Compliance - The company has adhered to various regulations regarding fundraising and fund management, including the establishment of tripartite agreements with banks and sponsors to ensure proper oversight [7][18][22]

Fundraising Overview - The company raised a total of RMB 610.55 million through the issuance of convertible bonds, with a net amount of RMB 600.35 million after deducting fees [1] - As of June 30, 2025, the company has utilized RMB 53.13 million of the raised funds, with a remaining balance of RMB 34.82 million [1][3] Fund Management - The company has established a dedicated account for managing the raised funds, in compliance with relevant laws and regulations [2][3] - A tripartite supervision agreement was signed with the underwriter and banks to clarify the rights and obligations of all parties involved [3] Fund Utilization - The company has allocated RMB 42.75 million of the raised funds for the construction of a liquid intelligent packaging production line [3] - The company temporarily supplemented working capital with RMB 50 million from the raised funds, which has positively impacted its operational capacity and financial condition [5] Project Changes - The implementation entity for the liquid intelligent packaging production line project has been changed from Zhejiang Meihua Packaging Machinery Co., Ltd. to Yongchuang Zhiyun (Zhejiang) Machinery Equipment Co., Ltd., with the project location also being updated [5][10] - The changes in project implementation do not affect the purpose, direction, or investment amount of the project [10] Compliance and Reporting - The company has ensured timely, truthful, accurate, and complete disclosure of information related to the raised funds, with no violations in fund management [6]

Core Points - The report details the fundraising and usage status of Wuxi Dekeli Optoelectronic Technology Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations and protecting investor rights [1][4]. Fundraising Overview - The company raised a total of RMB 1,179,763,200.00 through its initial public offering (IPO) at a price of RMB 48.51 per share, with a net amount of RMB 1,094,353,980.82 after deducting issuance costs [1]. - As of June 30, 2025, the company has used RMB 238,462,655.47 for investment projects and RMB 288,300,000.00 for working capital, leaving a balance of RMB 633,887,328.35 in unused funds [1]. - The company also raised RMB 217,149,951.88 through a simplified procedure for issuing shares to specific targets, with a net amount of RMB 217,149,951.88 and a remaining balance of RMB 117,280,466.63 as of the same date [1][2]. Fund Management - The company has established a fundraising management system to ensure proper use and storage of funds, adhering to laws and regulations [1][2]. - A tripartite supervision agreement has been signed with the sponsor and the bank to regulate the management of the raised funds [1][2]. Fund Usage Status - As of June 30, 2025, the company has not used idle funds for temporary working capital or made any prior investments or replacements with the raised funds [3][4]. - The company has engaged in cash management with idle funds, investing in low-risk financial products, with a total of RMB 60,967,733.33 used in the current year for the IPO funds [3][5]. Project Implementation - The company has not changed the implementation location or method for any fundraising projects, and there are no significant changes in project feasibility [4][5]. - The company has reported that the investment projects related to the IPO are progressing, with specific projects such as the high-speed optical module production line and optical transmission subsystem development experiencing delays [4][5].

Core Viewpoint - The company has approved the use of its own funds to pay for part of the fundraising project expenses, which will later be replaced with equivalent amounts from the raised funds, ensuring efficient management and compliance with regulations [1][5]. Group 1: Fundraising Overview - The company raised a total of RMB 217,149,951.88 through a specific stock issuance, with a net amount verified by an accounting firm [2]. - As of June 30, 2025, the company has utilized RMB 10,538.61 million of the planned investment total of RMB 21,715.00 million for its fundraising projects [2]. Group 2: Use of Own Funds - The company opted to use its own funds for certain project expenses due to restrictions on the fundraising account, particularly for overseas purchases [3][4]. - The process involves documenting transactions and ensuring that the funds are used solely for the intended projects, with a commitment to replace the used funds from the fundraising account within six months [4]. Group 3: Impact and Compliance - This approach is expected to enhance operational efficiency and ensure the smooth progress of fundraising projects without altering the intended use of the funds [4][5]. - The decision was approved by the company's board and audit committee, adhering to relevant legal and regulatory requirements [5].

Fundraising Overview - The company, Wuxi Dekeli Optoelectronic Technology Co., Ltd., has received approval from the China Securities Regulatory Commission for a specific stock issuance, raising a total of RMB 217,149,951.88 after deducting issuance costs [1][2] - The issuance price was set at RMB 63.51 per share, with a par value of RMB 1.00 per share [1] Fund Management and Regulatory Compliance - A special fundraising account has been established at Bank of China (Thailand) for the project "Dekeli Overseas R&D Production Base Construction Project," ensuring compliance with relevant regulations and protecting the interests of minority investors [2][3] - The company has signed a four-party supervision agreement involving itself, the project implementation entity Taclink (Thailand) Co., Ltd., Guotai Junan Securities Co., Ltd., and Bank of China (Thailand) [2][3] Agreement Details - The agreement stipulates that the funds raised must be used solely for the designated project and cannot be diverted for other purposes [3][4] - The supervising party, Guotai Junan Securities, is responsible for ongoing oversight of the fund management and usage, conducting at least biannual inspections [4][5] - The agreement will remain effective until all funds are fully utilized and the account is legally closed [5]

Fundraising Overview - The company raised a total of RMB 180 million through the issuance of convertible bonds, with a net amount of RMB 172.93 million after deducting underwriting fees and other expenses [1][3] - The funds were deposited in a designated account at Shanghai Pudong Development Bank [3] Fund Utilization and Balance - As of June 30, 2025, the company has utilized RMB 129.48 million of the raised funds, with RMB 3.04 million remaining in the dedicated account [2][4] - The total net amount of raised funds was RMB 173.33 million, with RMB 51.70 million allocated for permanent working capital [2][4] Fund Management - The company has established a management system for the use of raised funds, ensuring compliance with relevant laws and regulations [2] - A tripartite supervision agreement was signed with the underwriter and the bank to ensure proper management of the funds [3] Project Investment and Adjustments - The company has replaced RMB 15.70 million of self-raised funds with the raised funds for investment projects [5] - The "Intelligent Manufacturing Production Line Expansion Project" has been completed and is now operational, with surplus funds being allocated for working capital [6][10] Financial Performance - The company has not used idle funds for temporary working capital or invested in financial products during the reporting period [5][6] - The company has achieved cost savings in project implementation through various measures, including optimizing project layouts and reducing construction costs [10]

证券代码：600030 证券简称：中信证券 公告编号：临 2025-068 中信证券股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》及《上海证券 交易所上市公司自律监管指引第1号——规范运作》的规定，中信证券股份有限公 司（以下简称公司）编制了截至2025年6月30日A股配股及H股配股募集资金存放与 实际使用情况专项报告。具体如下： 公司经2020年度股东大会、2021年第一次A股类别股东会及2021年第一次H股 类别股东会审议通过，并经中国证券监督管理委员会《关于核准中信证券股份有 限公司配股的批复》 （证监许可〔2021〕3729号）、 《关于核准中信证券股份有限公 司发行境外上市外资股的批复》（证监许可〔2021〕3714号）文件核准，公司向A 股原股东及境外上市外资股股东配售新股，并已分别于2022年1月27日、3月4日成 功完成A股和H股配股工作。 一、募集资金基本情况 （一）募集资金到账情况 其中，公司于上海证券交易所公开发行1,552,021,6 ...

塞力斯医疗科技集团股份有限公司 募集资金管理办法 塞力斯医疗科技集团股份有限公司 募集资金管理办法 （2025 年 8 月） 第一章 总则 第一条 为完善塞力斯医疗科技集团股份有限公司（以下简称"公司"）治 理，规范公司对募集资金的使用和管理，提高募集资金的使用效率和效益，根据 《中华人民共和国公司法》 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司募集资金监管规则》《上海证券交易所股票上市规则》《上海证券交 易所上市公司自律监管指引第 1 号——规范运作》等法律法规、规章、规范性文 件及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"） 的规定，制定本办法。 第二条 本办法所称募集资金是指公司通过发行股票或者其他具有权益性质 的证券，向投资者募集并用于特定用途的资金，但不包括公司实施股权激励计划 募集的资金。 本办法所称超募资金是指实际募集资金净额超过计划募集资金金额的部分。 公司存在两次以上融资的，应当分别设置募集资金专户。超募资金也应当存 放于募集资金专户管理。 募集资金投资境外项目的，除符合第一款规定外，公司及保荐机构还应当采 取有效措施，确保投资于境外项目的募集资 ...